
The largest plasma fractionation facility in the Southern Hemisphere, the plant manufactures biotherapies that treat rare and life-threatening conditions including immunodeficiencies, neurological disorders, shock and burns. The facility processes domestic plasma from Australia, New Zealand, Taiwan, Hong Kong and Malaysia donor plasma, in addition to plasma sourced commercially through CSL Plasma. CSL Behring Broadmeadows is also home to a cell-culture biotechnology manufacturing plant that uses biotech processes to grow non-human genetically engineered cells that are purified into therapies for patients.